NBT Bank N A NY Sells 32,174 Shares of Pfizer Inc. (NYSE:PFE)

NBT Bank N A NY lowered its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 14.8% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 185,347 shares of the biopharmaceutical company's stock after selling 32,174 shares during the period. NBT Bank N A NY's holdings in Pfizer were worth $4,697,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of PFE. Norges Bank acquired a new stake in shares of Pfizer in the fourth quarter valued at about $2,328,986,000. Charles Schwab Investment Management Inc. increased its position in Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Starboard Value LP acquired a new position in shares of Pfizer in the 4th quarter worth approximately $407,730,000. Raymond James Financial Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth $274,694,000. Finally, Assenagon Asset Management S.A. raised its stake in Pfizer by 307.5% during the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after buying an additional 7,581,030 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. UBS Group upped their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Finally, Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Down 0.6%

Shares of NYSE PFE opened at $24.40 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a 50-day moving average price of $23.11 and a 200-day moving average price of $24.93. The stock has a market capitalization of $138.71 billion, a P/E ratio of 17.30, a P/E/G ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.82 earnings per share. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were issued a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.05%. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.